<DOC>
	<DOCNO>NCT00467519</DOCNO>
	<brief_summary>Currently , 5-component acellular pertussis vaccine license 5th dose US child age 4 6 years.This study aim provide evidence sero-protection , booster response safety formulation 5th dose . Primary Objective : - To compare immune response Tetanus toxoid , reduce diphtheria toxoid , acellular pertussis ( Tdap ) Vaccine Diphtheria , tetanus acellular pertussis ( DTaP ) vaccine ( antigen ) administer 5th dose give concurrently , child age 4 6 year . Secondary/Observational Objectives : - To compare immune response pertussis antigens Tdap Vaccine DTaP vaccine ( pertussis antigen ) administer 5th dose give concurrently , child age 4 6 year . - To present long-term immunogenicity 1- , 3- , 5-years post-vaccination long-term follow-up . - To describe safety profile follow vaccine administration .</brief_summary>
	<brief_title>Safety Immunogenicity Tdap Vaccine Compared DTaP Vaccine Children 4 6 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy , determine medical history physical examination . Aged 4 6 ( &lt; 7 ) year time study vaccination Day 0 . Signed date informed consent form approve Institutional Review Board ( IRB ) parent legally authorize representative . Signed date informed assent form subject require IRB . Able attend schedule visit Visit 1 Visit 2 able comply trial procedure . Subjects invited participate longterm immunogenicity followup study commitment participate longterm require inclusion criterion . Documented vaccination history 4 previous dos DAPTACEL accord recommend national immunization schedule Diphtheria , tetanus acellular pertussis ( DTaP ) . Exclusion Criteria : Participation another clinical trial 4 week precede trial vaccination . Planned participation another clinical trial original trial period . Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive past 3 month . Receipt vaccine within 30 day prior study vaccination , plan receive another vaccine within 30 day Visit 2 blood draw ( exception annual influenza vaccine ) . History diphtheria , tetanus pertussis infection ( confirm either serologically microbiologically ) . Thrombocytopenia bleed disorder contraindicate intra muscular vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Tetanus ; Diphtheria ; Pertussis ; ADACEL ; DAPTACEL</keyword>
</DOC>